The incremental capital will further strengthen our balance sheet, allowing the company to drive the continued commercial adoption of NeuroStar Advanced Therapy for Mental Health and with the continued goal of achieving cash flow breakeven in 2024," said Keith J. Sullivan, President and Chief Executive Officer of Neuronetics. "We would like to express our appreciation for SLR's ongoing support, and we look forward to continuing our long-term partnership." The maturity date of the credit facilities is March 29, 2028. The annual interest rate is equal to SOFR plus 5.65%, payable monthly in arrears.